At the company's slide show presentation at the Roth Capital investor conference about a week or so ago...
and then tell me what you see implies there is nothing to it....It is simply amazing. What RXII has developed will change the course of treatment for many years to company on many serious aliments, diseases, and conditions, that people suffer from daily. This one goes far beyond making some money on a stock.
I also feel the same way. Look at this way currently Regeneron (REGN) owns the macular degeneration market with its drug Eylea. What makes RXI's compound unique is that it doesn't just knock down the disease of macular degneration (VEGF) target like Eylea it also has a heal component to it with CTGF. That is what RXII has done combined VEGF Bevasirinib together with RXI-109 to do two things at the same time. So when you say revolutionary you sir are correct.
Which is why I think those 4 big funds are interested in buying shares on the open market for RXII to do a private dilution. They want to fund RXi's ophthalmology pipeline.
A few days ago when the stock once again took a swoon to below $5.50 instead of letting myself get stopped out, which is what I had planned to do, I cancelled the stop in time and actually bought more. I did that mostly because of your posts biotechpicklist.